Skip to main content
Publications
Marsal JR , Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights . Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Rivero-Ferrer E , Olesen M, Plana E , Aguado J , Saigi-Morgui N , Rubino A, Daoud SZ, Lei A, Perez-Gutthann S , Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C . Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany . Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA , Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct . J Rheumatol. 2009 Oct 1;36(10):2318-29.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA . OMERACT 8 workshop: fibromyalgia syndrome . J Rheumatol. 2007 Jun;34(6):1415-25.